Keytruda Improves Survival as Second-Line Treatment for Esophageal Cancer

Second-line treatment with pembrolizumab (Keytruda, Merck) reduced the risk of death by 31% in patients with advanced esophageal cancer compared with chemotherapy, according to new data from the KEYNOTE-181 phase 3 trial.
 
An estimated 17,650 adults in the United States will be diagnosed with esophageal cancer this year, with more than 572,000 estimated new cases worldwide, according to Merck. Patients diagnosed with the disease often face a poor prognosis, indicating the need for new therapeutic options. 
 
The trial evaluated pembrolizumab monotherapy as a second-line treatment compared with chemotherapy in more than 628 patients with advanced or metastatic esophageal or esophagogastric junction carcinoma. Patients received either a 200-mg fixed dose of pembrolizumab every 3 weeks or chemotherapy regimens, including docetaxel, paclitaxel, or irinotecan. Of these patients, 401 had squamous cell carcinoma and 222 had a PD-L1 Combined Positive Score (CPS) of ≥10.
 
Among patients with squamous cell carcinoma, the median overall survival (OS) was 8.2 months for those treated with pembrolizumab compared with 7.1 months in the chemotherapy group. In patients whose tumors expressed PD-L1 with a CPS of ≥10, the median OS in the pembrolizumab group was 9.3 months compared with a median OS of 6.7 months in the chemotherapy group. The estimated 12-month OS rate in these patients was 43% for pembrolizumab versus 20% for chemotherapy, according to the data. Compared with chemotherapy, treatment with pembrolizumab reduced the risk of death by 31%.
 
“The prognosis for patients diagnosed with esophageal cancer is poor, and for those who experience disease progression, there is no established standard of care, underscoring the need for improved therapies in the second-line setting,” Takashi Kojima, a professor at the Department of Gastroenterology and Gastrointestinal Oncology at the National Cancer Center Hospital, said in a statement. “The significant improvement in overall survival observed with Keytruda in patients with squamous cell carcinoma or adenocarcinoma whose tumors expressed PD-L1 with a CPS of 10 or greater represents an important scientific advancement and has the potential to benefit patients who currently have limited treatment options.”
 
Overall, the safety of pembrolizumab in the study was consistent with previous trials. Treatment-related adverse events occurred in 64.3% of patients taking pembrolizumab compared with 86.1% for chemotherapy, with most common adverse events being fatigue, hypothyroidism, decreased appetite, asthenia, nausea, and diarrhea.
 
This is the first time an anti-PD-1 therapy has demonstrated a survival benefit for this patient population, according to Merck.
 
Reference
 
Merck’s Keytruda (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1(CPS ≥10) [news release]. Merck’s website. https://www.mrknewsroom.com/news-release/oncology/mercks-keytruda-pembrolizumab-reduced-risk-death-31-percent-compared-chemother. Accessed January 15, 2019.
 
 
 
 
 



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Study recommends similar clinical thresholds for diagnosing and managing giant cell arteritis for patients of different ethnicities.
The approval of fedratinib (Inrebic, Celgene) provides another treatment option for patients with myelofibrosis, a rare bone marrow disorder.
Officials with the FDA have granted approval to entrectinib (Rozlytrek, Genentech) for 2 different cancer indications.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$